

2025

Year in Review



**PRECISION
CANCER**
CONSORTIUM

The PCC is a non-profit organization dedicated to driving global access to comprehensive genomic testing for all patients with cancer. The PCC is composed of and funded by: AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, and Lilly at the time of writing.

PCC-219 Date of preparation: March 2026

TABLE OF CONTENTS

Message from the PCC Chair	03
Mission statement	04
PCC strategic objectives	05
Executive Summary	06
Breaking news	07
2025 project highlights and accomplishments	08–09
Precision Medicine Awards 2025	10
Wayfinder spotlight	11
2025 PCC member companies	12
PCC Board of Directors	12
PCC members	13
Hear what the Board of Directors have to say	14–15
A look ahead at 2026	16
Become a PCC member	17–18
Glossary	18
Stay connected	19
PCC administration	19



GABRIELE ALLEGRI

Vice President, Global Commercial Precision Medicine,
Johnson & Johnson
Chair of the Board of Directors, Precision Cancer Consortium

Message from the Precision Cancer Consortium Chair

Equitable global access to precision cancer diagnostics holds the potential to better inform personalized cancer care.

The Precision Cancer Consortium (PCC) stands to unite global industry leaders through collaborative action to ensure that precision oncology and biomarker-informed, data-driven, equitable patient identification are integrated into routine care and clinical research.

Recent advances have underscored the critical role of comprehensive genomic profiling (CGP) and liquid biopsy (LBx) in enabling personalized cancer care, from identifying actionable mutations to tracking disease progression and identifying patients for clinical trial enrollment.

In 2025, the PCC made significant strides toward our mission and expanded our reach through strategic partnerships. With Avalere Health, we are driving a pilot initiative in Spain to identify and address systemic barriers to CGP at diagnosis, and the PCC is collaborating with a network of labs in Southern France to drive real-world access to LBx testing. Our Genomic Testing Cost Calculator and Lean Six Sigma tools empower stakeholders to advocate for and efficiently implement in-house comprehensive biomarker testing. Collectively, these initiatives facilitate accessible and informative biomarker testing.

Yet, disparities in access persist across geographies, institutions, and patient populations. The mission of PCC is to unite industry to close these gaps and ensure that every patient, regardless of location or background, has appropriate access to testing.

As we look to 2026, the Precision Cancer Consortium is entering a new phase defined by greater agility, deeper collaboration, and shared accountability. Through an evolved and flexible membership model, PCC invites stakeholders across the oncology ecosystem to move beyond alignment toward true co-creation. By engaging with PCC, organizations can actively shape the future of biomarker testing, contribute to disruptive, system-level initiatives, and collectively remove barriers that limit access to precision cancer diagnostics. Together, we can translate innovation into scalable solutions that deliver measurable impact for patients worldwide.

Our vision is clear: a world in which access to precision oncology diagnostics is not constrained by geography, infrastructure, or resources—but enabled by purposeful collaboration. I invite industry leaders, diagnostic partners, laboratories, policymakers, and innovators to join the PCC effort, to bring expertise, data, and ambition to the table, and to collaborate on initiatives that redefine standards of care and expand access for patients who need it most. Now is the time to act—together—to ensure that comprehensive biomarker testing becomes a reality for every patient with cancer.

Warm regards,

Gabriele Allegri

Mission

To drive global access to CGP for all patients with cancer, the PCC aims to make precision oncology and CGP the new normal.



PCC Strategic Objectives



Improve:

Improve global patient access to precision oncology in both routine care and clinical research

Educate:

Educate stakeholders and increase awareness on how comprehensive biomarker testing and data analysis can improve patient outcomes

Address:

Address the challenges of implementing precision oncology, including biomarker testing and data analysis, in healthcare systems to improve equitable treatment and outcomes

Executive Summary

7 ACTIVE PHARMA-BIOTECH COMPANIES*

ASTRAZENECA, BAYER, BRISTOL MYERS SQUIBB (BMS),
GSK,* LILLY, JOHNSON & JOHNSON, NOVARTIS, ROCHE*

27 CROSS-FUNCTIONAL ACTIVE PARTICIPANTS

7 VIRTUAL BOARD MEETINGS

2 IN-PERSON MEETINGS

CONGRESS PRESENCE, INCLUDING A
PCC BOOTH AT THE EUROPEAN CONGRESS OF
PATHOLOGY (ECP)

PCC NETWORKING SESSION AT ASCO,
ENCOURAGING COLLABORATION THROUGHOUT THE
WIDER PRECISION ONCOLOGY COMMUNITY

GLOBAL SCIENTIFIC STEERING COMMITTEE:
LEADING ONCOLOGISTS AND PATHOLOGISTS PROVIDE
EXPERT GUIDANCE TO THE PCC'S STRATEGIC DIRECTION

*During 2025, the PCC experienced a transition in membership. GSK concluded their participation, and we are pleased to welcome BMS as a new member. In addition, Bayer, Roche, and Novartis concluded their participation at the end of 2025.

Breaking News

PCC strengthens its membership with the addition of industry powerhouse BMS

The addition of pharmaceutical giant BMS marks a major step forward in the collaborative strength of the PCC. This membership represents more than a partnership—it marks a strategic milestone in the PCC’s capacity to drive meaningful change for patients with cancer.

BMS has extensive oncology diagnostic experience. Its commitment to improving equitable access to diagnostic technologies will be an invaluable contribution in driving global access to biomarker-informed, data-driven patient identification and personalized care in 2026, and beyond.

This addition complements PCC’s already impressive roster and heightens the consortium’s scope for achievement in delivering on its ambition to transform cancer diagnostics.

JILIAN GOLDING

Global Commercial Strategy Precision Medicine Lead, BMS, said in a statement regarding their PCC membership:

“We are excited to join the PCC and help expand its impact, building on the momentum the group has established with improving patient access to quality biomarker testing. These improvements are a critical step toward ensuring healthcare professionals have the information they need to best inform optimal management decisions.”



GABRIELE ALLEGRI

PCC Chair and Vice President for Global Commercial Precision Medicine at Johnson & Johnson Innovative Medicine, shared his enthusiasm for BMS joining the consortium, highlighting that:

“Their expertise will be invaluable as we collaborate to advance precision oncology and expand access to CGP. Together, we are working to make these innovations the standard of care, so that more patients receive the right care at the right time, improving outcomes and transforming lives.”



2025 Project Highlights and Accomplishments

Implementation of CGP into routine clinical practice

- 2025 saw the PCC's Access to CGP project team address the practical challenges of CGP implementation within regional healthcare systems, using Galicia, Spain, as a pilot site. The team evaluated adoption barriers and is working directly with governing bodies to enact policy changes that enable broader and more equitable access to CGP.
- With an anticipated launch in early 2026, the Access to CGP team is introducing *The Pathway to Precision Cancer Care: A Strategic and Operational Guide to Enhance Patient Access to CGP*. The interactive guide supports CGP integration into routine cancer care across varied healthcare settings. It is structured around nine key stakeholder-identified challenges, grouped under three core pillars: System Setup, Quality, and Workforce. The framework allows users to self-assess their current CGP status and provides a tailored report with recommended actions and tools to support implementation and accelerate patient access.

Adoption of LBx

- In an effort to demonstrate ways to improve LBx adoption for genomic profiling, the PCC's LBx project team has partnered with Professor Paul Hofman and the center of excellence University Côte d'Azur, in Nice, France. Professor Hofman and the PCC are collaborating with a wider network of laboratories in the South of France to address uptake barriers previously identified by PCC-funded primary market research. The team aims to implement a series of interventions designed to improve awareness and adoption, reducing logistical hurdles to access, and increasing testing volume to inform targeted therapy in major solid tumors.



[ASCO Steering Committee meeting](#)

- Featuring leading oncologist and pathologist key opinion leaders, this Steering Committee meeting was held in late May 2025 at ASCO to discuss and capture unique insights and recommendations for the implementation of CGP into routine clinical practice as well as the access and adoption of the LBx project. The Faculty also provided key insights into PCC's future prioritization strategy from the invaluable perspective of healthcare professionals, identifying the greatest barriers to testing and how the PCC can enact meaningful change.



[Reworked Genomic Testing Cost Calculator](#)

- The PCC, along with IQVIA, updated the PCC's Genomic Testing Cost Calculator to include additional actionable biomarkers as well as to incorporate testing costs in Euros and US Dollars to reflect 2024 costs. The updated Genomic Testing Cost Calculator compares the cost-effectiveness of different genomic testing approaches, such as next-generation sequencing (NGS), compared with single-gene sequential single-gene testing. This provides clinicians and policy makers with a robust financial use-case for adoption of multipanel testing.

ECP booth

- Growing awareness and cultivating collaboration—PCC seized the opportunity to increase consortium visibility, engaging with the wider pathologist community and showcasing PCC activities and tools, including the reworked Genomic Testing Cost Calculator.



Operational excellence: Lean Six Sigma modules [↗](#)

- A series of five modules tackling workflow-related biomarker testing inefficiencies. Lean Six Sigma drives a direct positive impact on patient selection, through laboratory workflow optimization, improving diagnostic testing, turnaround time, and quality.



ASCO networking session [↗](#)

- United in our vision and commitment to improving access to biomarker testing for all patients with cancer, PCC brought together likeminded advocates and members of industry (including Massive Bio, DeciBio, SOPHiA GENETICS, The Synergist, and others) to share their precision oncology experience and successes. These conversations embody the PCC's mission, bringing individuals together across companies and regions to improve patient access to precision oncology.





Precision Medicine Awards 2025

The PCC was privileged to have been shortlisted in the ‘Innovation and Collaboration of the Year’ category for the inaugural Precision Medicine Awards.

The awards celebrated the people and innovations driving better patient outcomes through personalized medicine. The 16 awards represented the pinnacle of excellence across a community of more than 40,000 professionals.

While the PCC did not ultimately win the category, it was an honor to be considered alongside so many other strong finalists. More importantly, it was inspiring and encouraging to see the breadth of work being undertaken across industry and academia to drive precision oncology forward through collaborative approaches.

“Our nomination highlights the importance of collaboration in the field of precision oncology. Connections across pharma, agencies, multidisciplinary experts, and the globe are needed now more than ever. I managed to find time at the awards night to talk to other accelerators of change, and it reminded me that change only happens when we break down silos and network with purpose.”

Gabriele Allegri

The Precision Medicine Awards evening took place on September 30, 2025, at the prestigious Church House Assembly Hall in Westminster, London, hosted by TV personality and former general practitioner, Paul Sinha.

The PCC would like to thank the organizers, Oxford Global, and the judging panel for their consideration.



Wayfinder Spotlight

Every successful project has someone who relies on their inner strategic compass to deliver successful outcomes.

At the core of the PCC is our dedicated group of members and advocates —our Wayfinders— their expertise and drive are what make meaningful progress possible.

Through the PCC Wayfinder Campaign, we celebrate individuals who chart the course for the future of precision oncology. Their dedication drives the success of our initiatives, ensuring impactful delivery of projects that improve outcomes for patients with cancer.

Their willingness to lead the pursuit of novel solutions, strengthen collaborations, and address complex challenges plays a vital role in guiding our progress. In recognizing their contributions, we highlight how vision can become action, and progress into lasting impact.



See our full list of PCC Wayfinders, and their outstanding contributions to driving our mission [here](#)

PCC Member Companies*

ASTRAZENECA
BAYER

BRISTOL MYERS SQUIBB
GSK

JOHNSON & JOHNSON
LILLY

NOVARTIS

PCC Board of Directors



Gabriele Allegri - PCC Chair
JOHNSON & JOHNSON
Vice President, Global
Commercial Precision Medicine



John Longshore - PCC Vice Chair
ASTRAZENECA
Head of Scientific Affairs for
Global Oncology Diagnostics



Sanne de Haas
BAYER
Translational Science
Lead



Jilian Golding
BRISTOL MYERS SQUIBB
Global Oncology Strategy,
Commercial Precision Medicine Lead



Alison Urvalek
LILLY
Executive Director, NSCLC
Strategy Lead



Lee-Anne Zinetti
NOVARTIS
Executive Director, Healthcare Systems,
Partnerships & Diagnostics, Oncology



Kimberly Noel
ROCHE
Global Lead of AI Advocacy &
Digital Health



Nicole St Jean, Vice Chair
GSK
Executive Director, External
Engagement – Precision Medicine
Portfolio Planning

*During 2025, the PCC experienced a transition in membership. GSK concluded their participation, and we are pleased to welcome BMS as a new member. In addition, Bayer, Roche, and Novartis concluded their participation at the end of 2025.

PCC Members

ASTRAZENECA

John Longshore
Elizabeth Sheppard
Tong Yin
Espen Walker
Alexander Yarunin

BAYER

Emmanuelle di Tomaso
Silvia Grosso
Jamie Grossman
Sarah Wang
Marisca Marian
Sanne de Haas

JOHNSON & JOHNSON

Gabriele Allegri
Ramin Dowlati
Andrea Stevens
Tricia Bal

NOVARTIS

Lee-Anne Zinetti

ROCHE

Benjamin Horbach
Kimberly Noel
Shruti Mathur

BRISTOL MYERS SQUIBB

Jilian Golding
Auditi DebRoy
Virginia Ip

LILLY

Bryce Portier
Tyler Marquart
Jay White
Alison Urvalek
Iris Simon

ASCO Chicago Board Meeting



ECP September Board Meeting

Hear What Board of Directors Members Have to Say



“The PCC’s efforts make a meaningful difference by bringing multiple companies together to pursue shared objectives. Instead of focusing on the priorities of a single organization, these projects promote worldwide access and enhance precision oncology care for patients. As biomarker testing technology advances beyond NGS, I am particularly enthusiastic about the consortium’s future developments in liquid biopsy for advanced uses and computational pathology. Our joint initiatives will have far-reaching effects and help improve global pathways for patient identification. AstraZeneca is honored to actively support and engage in PCC’s work across the entire spectrum of biomarker testing.”

John Longshore, PCC Vice Chair, AstraZeneca

“We strive toward a future where every patient, everywhere, benefits from the promise of precision medicine. Through the PCC, we unite global leaders to overcome testing barriers, harness cutting-edge science, and deliver transformative care. Together, we are not just advancing access to precision medicines, we are redefining what’s possible for patients worldwide.”

Jilian Golding and Greg Geissman, BMS



“At the Precision Cancer Consortium, we are proving that the most persistent challenges in healthcare—those embedded deep within the ecosystem—cannot be solved in isolation. Our coordinated and strategic efforts are helping to advance precision oncology from a promising concept toward a global standard of care. By uniting our collective expertise, we are addressing the technical and operational barriers that often limit access to comprehensive genomic profiling and advanced diagnostics, thereby accelerating the global shift toward truly data-driven cancer care. This collaboration is focused on building a pathway where patients worldwide have greater opportunity to benefit from precision-guided treatment.”

Shruti Mathur, Roche



“PCC’s goal to expand global access to precision oncology through biomarker testing aligns with Lilly’s belief that every patient deserves personalized, data-driven treatment. I’m excited to work alongside experts who share a commitment to translating cutting-edge science into tangible outcomes for patients. The opportunity to collaborate with leading researchers, clinicians, and innovators will only expedite us in reaching our common goals.”

Alison Urvalek, Lilly

“Despite significant progress in cancer research and treatment, there remain considerable challenges in ensuring that innovative, precision-based therapies reach all those who can benefit. By joining forces with leading organizations in the PCC, we recognize the critical importance of working together to drive broader access to targeted therapies that hold the promise of transforming patient outcomes. We remain dedicated to making a meaningful difference in the lives of people affected by cancer.”

Sanne de Haas, Bayer




A look ahead at 2026

As the field of precision oncology continues to evolve, PCC's strategic vision for 2026 aligns with emerging innovations while maintaining its core commitment to deliver equitable access and adoption of CGP and LBx—meeting its commitments through scaling successful pilots across additional countries and healthcare systems.

In response to recent advancements, such as the growing adoption and interest in digital pathology and AI, the consortium will focus on accelerating institutional uptake of computational pathology—a transformative field that leverages digitized pathology images to deliver quantitative insights for diagnosis, prognosis, and treatment.

PCC recognizes the criticality of accurate and reliable biomarker test results, standardization efforts to optimize laboratory protocols, and maximizing sample yield and quality. This standardization is vital for widespread clinical adoption, enabling consistent and accurate precision oncology diagnostics.

By addressing implementation barriers and fostering cross-functional collaboration, the PCC aims to ensure that these technologies support worldwide access to precision oncology for all patients with cancer.





Become a PCC member

The PCC is dedicated to a future where every person with cancer, regardless of who they are or where they live, can benefit from precision oncology. Through global collaboration, we work to make biomarker-informed, data-driven patient identification and personalized care standard practice.

1

- **Shape the future of biomarker testing in a way that you cannot do on your own:**

Challenges that are ecosystem-related cannot be solved by one stakeholder of the healthcare system alone. The PCC has an impartiality and collective credibility beyond a single pharmaceutical company. This allows the PCC to accomplish more than any individual company.

- ▶ **Case example:** Our Access to CGP project in Spain brings together the expertise of several PCC member companies who are working with the Galician health authorities to advance access to CGP. In parallel, they are developing additional tools and frameworks to support national precision medicine strategies globally.

2

- **Demonstrate your commitment to patients and the wider medical community:**

The PCC is a non-profit organization; our projects are never product-related or commercially driven. They are chosen based on improving biomarker testing for all patients with cancer.

- ▶ **Case example:** Through our LBx access project, PCC member companies are focused on identifying strategies to expand access to LBx technologies by advancing approaches that apply across multiple tumor types and remain biomarker-agnostic, ensuring that patients can benefit from these tools regardless of the specific molecular characteristics of their disease.

3

- **Maximize resource utilization and reach:**

Collaborate with fellow subject matter experts to share resources and leverage existing materials for new audiences to extend reach.

- ▶ **Case example:** Examples of projects delivered by individual member companies and distributed via the PCC include:
 1. Lean Six Sigma training modules (**originally from AstraZeneca**)
 2. NGS Genomic Testing Cost Calculator (**originally from Bayer**)
 3. Webinars on expert insights on pathology in clinical trials (**originally from Lilly**)

PCC membership

Working collaboratively to increase our collective impact is central both to our successes to date and to our future. In order to allow more companies, big and small, to contribute to our shared mission, we would be delighted to discuss collaboration opportunities outside of a full membership model. This will allow targeted contributions at an individual project level. Through this more flexible approach, we have reduced the barriers to entry and have opened the door to further partnerships to deliver comprehensive biomarker testing worldwide.



Ready to join?

Become part of a global collaborative effort to make precision oncology accessible for all.

[Become a member now](#)



Need more details?

Contact us to discuss the best option for your organization.

[Contact us](#)

Glossary

- **AI:** Artificial intelligence
- **ASCO:** American Society of Clinical Oncology
- **BMS:** Bristol Myers Squibb
- **CGP:** Comprehensive genomic profiling
- **ECP:** European Congress of Pathology
- **LBx:** Liquid biopsy
- **NGS:** Next-generation sequencing
- **NSCLC:** Non-small cell lung cancer
- **PCC:** Precision Cancer Consortium

STAY CONNECTED!



Follow us
on LinkedIn



Visit our
website



Email Us



PCC ADMINISTRATOR

Inquiries regarding PCC and membership can be submitted to the PCC's administrator at: pcc@indigomedical.co.uk or via the contact form on the PCC website: precisioncancerconsortium.com.



Arian Vahidansari
Senior Medical Writer
arian.vahidansari@indigomedical.co.uk



Andreas Sakka
Scientific and Operations Director
Andreas.Sakka@indigomedical.co.uk



**PRECISION
CANCER**
CONSORTIUM